Clinical trials
Advanced Neuroendocrine Carcinoma clinical trials
Below are recruiting advanced neuroendocrine carcinoma clinical trials, each written for real people, not researchers. We’re tracking 64 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Birmingham, AlabamaAges 18 years+ - NCT06157827RecruitingPhase 1/Phase 2
Testing LBL-024 plus chemo for advanced neuroendocrine carcinoma
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
Hefei, AnhuiAges 18–75 - NCT07518602RecruitingPhase 2
Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT06070740RecruitingPhase 2
Durvalumab Plus Chemo for Advanced Gastrointestinal NEC
This trial tests a combination of durvalumab (an immunotherapy drug) plus a chemotherapy called XELOX as the first treatment for advanced gastrointestinal neuroendocrine carcinoma (NEC). It aims to see if the combination works better than chemo alone.
Beijing, Beijing MunicipalityAges 18–75 - NCT07429851Recruiting
Comparing thymus, lung, and pancreas neuroendocrine tumors
This trial is studying well-differentiated high-grade neuroendocrine tumors that start in the thymus, lung, or pancreas. It compares these tumors to understand them better and find better treatments.
Milan, ItalyAges Any age - NCT07215988Recruiting
Studying insurance for skin cancer treatment
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
Columbus, OhioAges 18 years+ - NCT07061080RecruitingPhase 2
Tarlatamab for advanced digestive neuroendocrine cancer
This trial tests a new drug called Tarlatamab for people with advanced neuroendocrine carcinoma (a rare and aggressive cancer) of the digestive system that has stopped responding to prior chemotherapy. The drug targets a protein called DLL3 found on some tumors, and researchers hope it can shrink or slow tumor growth.
Brest, BrestAges 18 years+ - NCT07006727RecruitingPhase 1
Targeted radiation therapy for DLL3-positive advanced cancers
This study tests a new targeted radiation therapy (called [225Ac]Ac-ETN029) for people with advanced cancers that have a protein called DLL3 on their cells. The treatment is designed to deliver radiation directly to cancer cells, and the goal is to see if it is safe and effective.
Iowa City, IowaAges 18–100 - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT05746208RecruitingPhase 2
Lenvatinib plus pembrolizumab for advanced grade 3 NET tumors
This trial studies lenvatinib plus pembrolizumab to treat well-differentiated grade 3 neuroendocrine tumors (NETs) that cannot be fully removed by surgery or are locally advanced. It aims to shrink the tumor or slow its growth after the disease shows progression.
San Francisco, CaliforniaAges 18 years+ - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT06041516RecruitingPhase 1
New drug ADCT-701 for neuroendocrine and nerve tumors
This trial tests a new drug called ADCT-701 for people with certain rare cancers (neuroendocrine tumors, adrenal cancer, or a type of nerve tumor) that have come back or spread. The drug is an antibody-drug conjugate, which works like a targeted missile to kill cancer cells while trying to spare healthy ones.
Bethesda, MarylandAges 18–120 - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT06372626RecruitingPhase 1/Phase 2
ZG005 with chemo for advanced neuroendocrine cancer
This trial tests a new drug (ZG005) combined with two standard chemotherapy drugs (etoposide and cisplatin) for people with advanced neuroendocrine carcinoma that has spread or come back. The goal is to see if the combination works better than the standard treatment alone.
Beijing, Beijing MunicipalityAges 18–70 - NCT06440057RecruitingPhase 1/Phase 2
Study of ZG006 for advanced lung and neuroendocrine cancers
This trial is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma. The study has two parts: first finding the right dose, then testing it in more people with neuroendocrine carcinoma.
Beijing, Beijing MunicipalityAges 18–75 - NCT06889493RecruitingPhase 1
SVV-001 plus immunotherapy for neuroendocrine cancers
This trial tests a new virus-based treatment (SVV-001) combined with two immunotherapy drugs (nivolumab and ipilimumab) for people with advanced neuroendocrine cancers that have gotten worse after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Miami, FloridaAges 18 years+ - NCT06893783RecruitingPhase 2
Tarlatamab for advanced extrapulmonary neuroendocrine carcinoma
This study tests a drug called tarlatamab for people with a rare cancer called extrapulmonary neuroendocrine carcinoma that has grown or returned after standard chemotherapy. The goal is to see if tarlatamab can help shrink tumors and improve outcomes.
SeoulAges 19 years+ - NCT06937905RecruitingPhase 3
Tarlatamab vs chemo for advanced NEC after one prior treatment
This trial tests a new immunotherapy drug called tarlatamab, which targets the DLL3 protein on cancer cells, versus standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC). You may qualify if your NEC has gotten worse after just one prior platinum chemotherapy and your tumor has DLL3.
AngersAges 18 years+ - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
Huntsville, AlabamaAges 18 years+ - NCT07278479RecruitingPhase 1/Phase 2
Study of a targeted radiation therapy for small cell lung cancer
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT06398444RecruitingPhase 2/Phase 3
Lutetium-177 treatment for advanced neuroendocrine tumors
This trial tests a radioactive drug called Lutetium-177 Oxodotreotide (a type of PRRT) for people with advanced neuroendocrine tumors that have already been treated with other therapies and are still growing. The drug targets somatostatin receptors on tumor cells to deliver radiation directly to the cancer.
Shanghai, Shanghai MunicipalityAges 12 years+ - NCT06943521RecruitingPhase 1/Phase 2
Study of MT-4561 for advanced solid tumors
This trial tests a new drug called MT-4561 in people with advanced solid tumors that have not responded to prior treatments. It aims to see if the drug can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06246630Recruiting
Personalized drug testing for advanced pancreatic neuroendocrine tumors
This trial uses a lab-grown model of your tumor (called an organoid) to test which drugs might work best for you. It is for people with advanced pancreatic neuroendocrine tumors who cannot have surgery.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07038096RecruitingPhase 1/Phase 2
Testing ZG006 and ZG005 for lung and neuroendocrine cancers
This trial tests two new drugs, ZG006 and ZG005, for people with advanced small cell lung cancer or neuroendocrine carcinoma. The goal is to see if these drugs can shrink tumors or slow cancer growth.
Guanzhou, GuangdongAges 18–70
Hear when a new Advanced Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced neuroendocrine carcinoma?
- Yes. Clin2 currently lists 64 recruiting advanced neuroendocrine carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced neuroendocrine carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced neuroendocrine carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.